RecruitingPhase 1NCT07172971

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

duCHennE caRdiomyopathy mItigation Sglt2 inHibitor

Sponsor

Vanderbilt University Medical Center

Enrollment

10 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Duchenne Muscular Dystrophy (DMD)

Summary

This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.

Eligibility

Sex: MALEMin Age: 8 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SGLT-2 inhibitor and a drug called SGLT2 inhibitor for people with duchenne muscular dystrophy (dmd). The study is currently recruiting participants at 1 location. People eligible for this study include men aged 8 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.